Cargando…

Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance

Introduction: The genetic basis of neuroendocrine tumors (NETs), whose incidence is continuously increasing, is still not fully defined. The majority of NETs are sporadic, and only a small percentage occur as part of hereditary genetic syndromes. However, the associations of multiple genetic variant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurzyńska, Anna, Pach, Dorota, Skalniak, Anna Elżbieta, Stefańska, Agnieszka, Opalińska, Marta, Przybylik-Mazurek, Elwira, Hubalewska-Dydejczyk, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573749/
https://www.ncbi.nlm.nih.gov/pubmed/36233401
http://dx.doi.org/10.3390/jcm11195536
_version_ 1784810950763741184
author Kurzyńska, Anna
Pach, Dorota
Skalniak, Anna Elżbieta
Stefańska, Agnieszka
Opalińska, Marta
Przybylik-Mazurek, Elwira
Hubalewska-Dydejczyk, Alicja
author_facet Kurzyńska, Anna
Pach, Dorota
Skalniak, Anna Elżbieta
Stefańska, Agnieszka
Opalińska, Marta
Przybylik-Mazurek, Elwira
Hubalewska-Dydejczyk, Alicja
author_sort Kurzyńska, Anna
collection PubMed
description Introduction: The genetic basis of neuroendocrine tumors (NETs), whose incidence is continuously increasing, is still not fully defined. The majority of NETs are sporadic, and only a small percentage occur as part of hereditary genetic syndromes. However, the associations of multiple genetic variants have been found as clinically relevant in several neoplasms. The aim of this study was to evaluate whether selected, literature-based genetic variants may have a potential role in NET susceptibility and clinical outcome in Polish patients. Materials/methods: A total of 185 patients recruited from one clinical center were enrolled. In the first part of the study, the molecular analysis including four single-nucleotide variants (rs8005354 (DAD1, NM_001344 intronic T/C substitution), rs2069762 (T/G substitution in the promoter region of the IL2 NM_000586), rs3731198 (CDKN2A, NM_000077 intronic A/G substitution), and rs1800872 (C/A substitution in the promoter region of the IL10 NM_000572)) was performed in 107 participants (49 patients with NETs with different primary site NETs and a control group of 58 healthy adult volunteers). In the second stage, the same single-nucleotide polymorphisms (SNPs) were assessed in 127 patients with NET and analyzed in terms of clinical data (primary site, serum CgA concentration, and metastatic disease). Results: The analysis of homozygotes revealed a statistically significant higher prevalence of TT homozygotes of variant rs3731198 in the control group (p = 0.0209). In NET patients, there was a statistically significant higher prevalence of GG homozygotes of variant rs1800872 (p = 0.003). There was a statistically significant correlation between the rs3731198 variant and lymph node metastases (p = 0.0038 with Bonferroni correction). Conclusions: Our study indicates that GG homozygotes of variant rs1800872 are more often observed in NET patients, while TT homozygotes of variant rs3731198 are less frequent in this group. The rs3731198 variant may be related to an increased risk of lymph node metastasis. Further, larger multicenter studies are warranted to evaluate the potential genetic factors of sporadic NETs.
format Online
Article
Text
id pubmed-9573749
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95737492022-10-17 Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance Kurzyńska, Anna Pach, Dorota Skalniak, Anna Elżbieta Stefańska, Agnieszka Opalińska, Marta Przybylik-Mazurek, Elwira Hubalewska-Dydejczyk, Alicja J Clin Med Article Introduction: The genetic basis of neuroendocrine tumors (NETs), whose incidence is continuously increasing, is still not fully defined. The majority of NETs are sporadic, and only a small percentage occur as part of hereditary genetic syndromes. However, the associations of multiple genetic variants have been found as clinically relevant in several neoplasms. The aim of this study was to evaluate whether selected, literature-based genetic variants may have a potential role in NET susceptibility and clinical outcome in Polish patients. Materials/methods: A total of 185 patients recruited from one clinical center were enrolled. In the first part of the study, the molecular analysis including four single-nucleotide variants (rs8005354 (DAD1, NM_001344 intronic T/C substitution), rs2069762 (T/G substitution in the promoter region of the IL2 NM_000586), rs3731198 (CDKN2A, NM_000077 intronic A/G substitution), and rs1800872 (C/A substitution in the promoter region of the IL10 NM_000572)) was performed in 107 participants (49 patients with NETs with different primary site NETs and a control group of 58 healthy adult volunteers). In the second stage, the same single-nucleotide polymorphisms (SNPs) were assessed in 127 patients with NET and analyzed in terms of clinical data (primary site, serum CgA concentration, and metastatic disease). Results: The analysis of homozygotes revealed a statistically significant higher prevalence of TT homozygotes of variant rs3731198 in the control group (p = 0.0209). In NET patients, there was a statistically significant higher prevalence of GG homozygotes of variant rs1800872 (p = 0.003). There was a statistically significant correlation between the rs3731198 variant and lymph node metastases (p = 0.0038 with Bonferroni correction). Conclusions: Our study indicates that GG homozygotes of variant rs1800872 are more often observed in NET patients, while TT homozygotes of variant rs3731198 are less frequent in this group. The rs3731198 variant may be related to an increased risk of lymph node metastasis. Further, larger multicenter studies are warranted to evaluate the potential genetic factors of sporadic NETs. MDPI 2022-09-21 /pmc/articles/PMC9573749/ /pubmed/36233401 http://dx.doi.org/10.3390/jcm11195536 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kurzyńska, Anna
Pach, Dorota
Skalniak, Anna Elżbieta
Stefańska, Agnieszka
Opalińska, Marta
Przybylik-Mazurek, Elwira
Hubalewska-Dydejczyk, Alicja
Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
title Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
title_full Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
title_fullStr Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
title_full_unstemmed Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
title_short Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance
title_sort prevalence of selected single-nucleotide variants in patients with neuroendocrine tumors—potential clinical relevance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573749/
https://www.ncbi.nlm.nih.gov/pubmed/36233401
http://dx.doi.org/10.3390/jcm11195536
work_keys_str_mv AT kurzynskaanna prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance
AT pachdorota prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance
AT skalniakannaelzbieta prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance
AT stefanskaagnieszka prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance
AT opalinskamarta prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance
AT przybylikmazurekelwira prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance
AT hubalewskadydejczykalicja prevalenceofselectedsinglenucleotidevariantsinpatientswithneuroendocrinetumorspotentialclinicalrelevance